MAZE earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -10.36. Updated 2026-07-23.
Maze Therapeutics (MAZE) Research Hub
Maze Therapeutics (MAZE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 24.6 USD (+0.08%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -10.36, market cap 1.57B. This hub links to the full technical, earnings and options research available for MAZE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 24.6 USD (+0.08%) |
| 52-week range | 23.67 USD – 33.49 USD |
| Trend regime | Range |
| 14-day RSI | 33.1 (Bearish) |
| Trailing P/E | -10.36 |
| Market cap | 1.57B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for MAZE
Covered Call on MAZE: how it works, illustrative setup around the real 24.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MAZE: how it works, illustrative setup around the real 24.6 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MAZE: how it works, illustrative setup around the real 24.6 USD price, max profit/loss, breakeven and when to use it. Educational.
MAZE technical analysis: range, last 24.6 USD, RSI 33.1, 52w range 23.67 USD–33.49 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MAZE in?
Maze Therapeutics (MAZE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MAZE in an uptrend or downtrend?
As of 2026-09-11, MAZE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MAZE's trailing P/E ratio?
MAZE's trailing P/E is -10.36, with a market cap of 1.57B. See the earnings research page for full valuation detail.
When does MAZE next report earnings?
MAZE is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.76 USD.